Literature DB >> 16569878

Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.

Toshihiro Nishizawa1, Hidekazu Suzuki, Kumiko Kurabayashi, Tatsuhiro Masaoka, Hiroe Muraoka, Mikiji Mori, Eisuke Iwasaki, Intetsu Kobayashi, Toshifumi Hibi.   

Abstract

A high resistance rate (47.9%) to gatifloxacin (GAT; 8-methoxy fluoroquinolone) in Helicobacter pylori (H. pylori) strains from 48 Japanese patients is observed after unsuccessful H. pylori eradication. A significant association between MICs for GAT equal to or above 1 microg/ml and mutations of the gyrA gene of H. pylori was demonstrated.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16569878      PMCID： PMC1426923          DOI： 10.1128/AAC.50.4.1538-1540.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy.

Authors:  M Heep; M Kist; S Strobel; D Beck; N Lehn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-07       Impact factor: 3.267

2.  In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump.

Authors:  Naidan Luo; Orhan Sahin; Jun Lin; Linda O Michel; Qijing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

3.  Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.

Authors:  A Pilotto; M Franceschi; M Rassu; G Leandro; L Bozzola; F Furlan; F Di Mario
Journal:  Dig Liver Dis       Date:  2000-11       Impact factor: 4.088

4.  Compound efflux in Helicobacter pylori.

Authors:  Amy Kutschke; Boudewijn L M de Jonge
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

5.  [Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid].

Authors:  C Toro; J García-Samaniego; J Carbó; A Iñiguez; T Alarcón; M López-Brea; M Baquero
Journal:  Rev Esp Quimioter       Date:  2001-06       Impact factor: 1.553

6.  Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis.

Authors:  T Masaoka; H K SuzukiKurabayashi; A G Kamiya; H Ishii
Journal:  Aliment Pharmacol Ther       Date:  2004-07       Impact factor: 8.171

7.  In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children.

Authors:  Shigeru Fujimura; Seiichi Kato; Kazuie Iinuma; Akira Watanabe
Journal:  J Med Microbiol       Date:  2004-10       Impact factor: 2.472

8.  Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.

Authors:  F Perri; V Festa; A Merla; F Barberani; A Pilotto; A Andriulli
Journal:  Aliment Pharmacol Ther       Date:  2003-10-15       Impact factor: 8.171

9.  The status of antimicrobial resistance of Helicobacter pylori in eastern Europe.

Authors:  L Boyanova; A Mentis; M Gubina; E Rozynek; G Gosciniak; S Kalenic; V Göral; L Kupcinskas; B Kantarçeken; A Aydin; A Archimandritis; D Dzierzanowska; A Vcev; K Ivanova; M Marina; I Mitov; P Petrov; A Ozden; M Popova
Journal:  Clin Microbiol Infect       Date:  2002-07       Impact factor: 8.067

10.  Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.

Authors:  Ala I Sharara; Hani F Chaar; Eddy Racoubian; Oussayma Moukhachen; Kassem A Barada; Fadi H Mourad; George F Araj
Journal:  Helicobacter       Date:  2004-06       Impact factor: 5.753
View more
  25 in total

1.  Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.

Authors:  Hidekazu Suzuki; Toshihiro Nishizawa; Hiroe Muraoka; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

2.  Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic.

Authors:  Muhammad Miftahussurur; Modesto Cruz; Phawinee Subsomwong; José A Jiménez Abreu; Celso Hosking; Hiroyuki Nagashima; Junko Akada; Yoshio Yamaoka
Journal:  Am J Trop Med Hyg       Date:  2017-02-13       Impact factor: 2.345

Review 3.  Helicobacter pylori and gastric cancer.

Authors:  Hidekazu Suzuki; Eisuke Iwasaki; Toshifumi Hibi
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

4.  Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Hitoshi Tsugawa; Hiroe Muraoka; Juntaro Matsuzaki; Kenro Hirata; Fumiaki Ikeda; Masahiko Takahashi; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2011-04-12       Impact factor: 5.191

5.  Quinolone resistance in Helicobacter pylori isolates in Germany.

Authors:  Erik Glocker; Hans-Peter Stueger; Manfred Kist
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

6.  Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.

Authors:  Juntaro Matsuzaki; Hidekazu Suzuki; Toshihiro Nishizawa; Kenro Hirata; Hitoshi Tsugawa; Yoshimasa Saito; Sawako Okada; Seiichiro Fukuhara; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

7.  Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

Authors:  Kathleen R Jones; Jeong-Heon Cha; D Scott Merrell
Journal:  Curr Drug ther       Date:  2008-09-01

Review 8.  Helicobacter pylori: present status and future prospects in Japan.

Authors:  Hidekazu Suzuki; Toshifumi Hibi; Barry James Marshall
Journal:  J Gastroenterol       Date:  2007-02-16       Impact factor: 7.527

9.  Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations.

Authors:  Kazunari Murakami; Tadayoshi Okimoto; Masaaki Kodama; Jin Tanahashi; Toshio Fujioka; Fumiaki Ikeda; Hiroe Muraoka; Motoko Takigawa; Takeshi Saika; Miyuki Hasegawa; Intetsu Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

10.  Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori.

Authors:  Emmanuelle Cambau; Vera Allerheiligen; Céline Coulon; Céline Corbel; Christine Lascols; Lionel Deforges; Claude-James Soussy; Jean-Charles Delchier; Francis Megraud
Journal:  J Clin Microbiol       Date:  2009-09-16       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.